


Eli Lilly introduces Mounjaro (tirzepatide) for treatment of obesity and type 2 diabetes

20 March 2025 | News

The once-weekly injection is a prescription medicine and should be used under medical advice



Eli Lilly and Company (India) has announced the launch of Mounjaro in single-dose vial presentation following the marketing authorisation from the Central Drugs Standard Control Organisation (CDSCO).

It is a first-of-its-kind treatment for obesity, overweight, and type 2 diabetes that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors.

Mounjaro is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition. Mounjaro is also indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Tirzepatide was evaluated in two robust global clinical development programs: the SURMOUNT - 1 trials for chronic weight management and the SURPASS trials for type 2 diabetes.

India has about 101 million people living with diabetes and nearly half of these in the adult patients category are being inadequately treated with suboptimal glycemic control. Obesity, a chronic relapsing disease, is a major risk factor for

diabetes, is linked to over 200 health complications, including hypertension, dyslipidemia, coronary heart disease, and obstructive sleep apnea. As of 2023, adult obesity prevalence in India stood at around 6.5%, affecting nearly 100 million people.

"Obesity and diabetes are recognised as serious conditions linked to various life-limiting health complications, making effective and sustained treatment critical. We are thrilled to introduce Mounjaro in India to address these unmet medical needs. Mounjaro may offer a new approach to metabolic health management, providing healthcare providers with an innovative option to treat these diseases", said Dr Manish Mistry, Senior Medical Director, Lilly India.